- Home
- MRK
MRK
Merck & Company Inc. (new)
as 07-26-2024 4:00pm EST
Upcoming Earnings Alert:
Get ready for potential market movements as Merck & Company Inc. (new) MRK prepares to release earnings report on 30 Jul 2024.
| Founded: | 2000 | Country: | United States |
| Employees: | N/A | City: | KENILWORTH |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | $135.36 | AVG Volume (30 days): | 9.1M |
| Analyst Decision: | Buy | Number of Analysts: | 11 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 0.90 | EPS Growth: | -82.42 |
| 52 Week Low/High: | $99.14 - $134.63 | Next Earning Date: | 07-30-2024 |
| Revenue: | $61,402,000,000 | Revenue Growth: | 6.11% |
| Revenue Growth (this year): | 7.94% | Revenue Growth (next year): | 7.34% |
Stock Insider Trading Activity of Merck & Company Inc. (new) (MRK)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 10% Owner | Mar 11 '24 | Buy | $23.00 | 21,397,205 | $492,135,715.00 | 1,000 | SEC Form 4 |
Latest Merck & Company Inc. (new) News
MRK Breaking Stock News: Dive into MRK Ticker-Specific Updates for Smart Investing
Business Wire
13 hours ago
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First-Line Treatment for Patients With Unresectable or Metastatic Urothelial Carcinoma
Clinical Trials Arena
3 days ago
MSD reports positive topline data from Phase IIb/III RSV trial in infants
Benzinga
3 days ago
Merck Competes With Sanofi/AstraZeneca As Its RSV Treatment Drug Meets Primary Goal In Late-Stage Study In Infants
Business Wire
3 days ago
Merck Announces Fourth-Quarter 2024 Dividend
Zacks
3 days ago
Should You Buy, Sell or Hold Merck (MRK) Ahead of Q2 Earnings?
Motley Fool
3 days ago
Billionaires Are Loading Up on This Surging Dow Stock. Should You?
Simply Wall St.
4 days ago
Merck & Co., Inc. (NYSE:MRK) is largely controlled by institutional shareholders who own 78% of the company
BioPharma Dive
4 days ago
Merck claims late-stage study success for RSV antibody
Compare MRK vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MRK Merck & Company Inc. (new) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.